APA (7th ed.) Citation

TA, Y., PM, L., DJ, W., S, H., KP, P., JB, H., . . . M, M. (2023). A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(5), 888. https://doi.org/10.1158/1078-0432.CCR-22-1449

Chicago Style (17th ed.) Citation

TA, Yap, et al. "A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 29, no. 5 (2023): 888. https://doi.org/10.1158/1078-0432.CCR-22-1449.

MLA (9th ed.) Citation

TA, Yap, et al. "A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 29, no. 5, 2023, p. 888, https://doi.org/10.1158/1078-0432.CCR-22-1449.